Diapocynin, a dimer of the NADPH oxidase inhibitor apocynin, reduces ROS production and prevents force loss in eccentrically contracting dystrophic muscle.
Hesham M Ismail, Leonardo Scapozza, Urs T Ruegg, Olivier M Dorchies
Index: PLoS ONE 9(10) , e110708, (2014)
Full Text: HTML
Abstract
Elevation of intracellular Ca2+, excessive ROS production and increased phospholipase A2 activity contribute to the pathology in dystrophin-deficient muscle. Moreover, Ca2+, ROS and phospholipase A2, in particular iPLA2, are thought to potentiate each other in positive feedback loops. NADPH oxidases (NOX) have been considered as a major source of ROS in muscle and have been reported to be overexpressed in muscles of mdx mice. We report here on our investigations regarding the effect of diapocynin, a dimer of the commonly used NOX inhibitor apocynin, on the activity of iPLA2, Ca2+ handling and ROS generation in dystrophic myotubes. We also examined the effects of diapocynin on force production and recovery ability of isolated EDL muscles exposed to eccentric contractions in vitro, a damaging procedure to which dystrophic muscle is extremely sensitive. In dystrophic myotubes, diapocynin inhibited ROS production, abolished iPLA2 activity and reduced Ca2+ influx through stretch-activated and store-operated channels, two major pathways responsible for excessive Ca2+ entry in dystrophic muscle. Diapocynin also prevented force loss induced by eccentric contractions of mdx muscle close to the value of wild-type muscle and reduced membrane damage as seen by Procion orange dye uptake. These findings support the central role played by NOX-ROS in the pathogenic cascade leading to muscular dystrophy and suggest diapocynin as an effective NOX inhibitor that might be helpful for future therapeutic approaches.
Related Compounds
Related Articles:
2015-04-13
[Biomacromolecules 16(4) , 1382-9, (2015)]
2014-12-08
[Biomacromolecules 15(12) , 4561-9, (2014)]
2014-10-01
[Eur. J. Pharm. Biopharm. 88(2) , 406-14, (2014)]
2015-02-15
[Food Chem. 169 , 28-33, (2014)]
2015-04-30
[Int. J. Pharm. 484(1-2) , 283-91, (2015)]